Introduction {#sec1}
============

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder in which local deposition of anti-nuclear antibodies and activation of the complement system take part. The most common manifestations are malar rash, oral aphthous ulcers, arthralgia, photosensitivity and nephritis. Pediatric cases account for 10--20% of all patients with SLE and have poorer prognosis with higher incidence of renal and central nervous system involvement \[[@cit0001]\].

Avascular necrosis (AVN), also known as osteonecrosis, is a disorder characterized by cessation of the blood supply and subsequent death of the bone marrow and trabecular bone. It is a well-known complication of SLE \[[@cit0002], [@cit0003]\]. Avascular necrosis affects particularly femoral head, femoral condyles, proximal tibia and ankles. Multifocal AVN is found in approximately 57--81% of patients with AVN and is characterized by the involvement of three or more separate anatomic sites \[[@cit0002], [@cit0004]\].

In view of the lack of information on prevalence and risk factors of AVN in juvenile SLE (jSLE), herein we describe a distinctive pediatric patient with neuropsychiatric (NP) SLE, who subsequently developed symptomatic multifocal AVN resembling polyarthritis.

Case report {#sec2}
===========

A 13-year-old female patient was referred to Department of Pediatric Rheumatology with bilateral knee, wrist and hand pain and swelling for the last 3 months and recurrent oral aphthous ulcers for 5 years. The patient had suffered from severe headache and visual/auditory hallucinations lasting two weeks before her joint complaints. Physical examination was normal except for the malar rash and arthritis in wrists and ankles.

Initial laboratory results revealed normal urine analysis, leukopenia, slight thrombocytopenia, mildly elevated liver enzymes and markedly reduced serum complement levels. Antinuclear antibody (ANA), anti-double-stranded DNA (dsDNA) and anti-SSA antibodies were positive, whereas antibodies for other extractable nuclear antigens (ENA) were negative. Autoimmune hepatitis spectrum antibody as smooth muscle antibody (SMA) was positive, whereas liver-kidney-muscle-1 antibody (anti-LKM1) was negative. We diagnosed the patient as having SLE and autoimmune hepatitis (AIH) and initiated treatment with methylprednisolone, in a maximum oral dose of 48 mg/day, hydroxychloroquine and azathioprine.

For the next 4 months, arthritis and skin rash were alleviated, but NP SLE symptoms increased. Central nervous system imaging with magnetic resonance (MR) and angiography did not reveal any organic abnormalities. Nonetheless we ceased azathioprine and initiated risperidone and monthly intravenous cyclophosphamide.

Neuropsychiatric symptoms improved and serum complement levels returned to normal; thus we tapered the methylprednisolone dose to 8 mg/day. Thereafter, the patient began to suffer from bilateral knee pain and swelling. At the 4^th^ dose of cyclophosphamide and after a 5.3 g (94.7 mg/kg) cumulative dose of methylprednisolone, a diagnosis of symptomatic multifocal AVN was made by detecting typical geographical lesions on MR imaging although classical radiography was normal ([Fig. 1](#f0001){ref-type="fig"}).

![Characteristic lesions of avascular necrosis on magnetic resonance imaging. Avascular necrosis with geographic-appearing lesions on coronal T1 image of the right distal tibia (A) and sagittal T1-weighted images of the right knee (proximal tibia and distal femur) (B). Coronal T2 magnetic resonance image shows bilateral hyperintensity at the bottom of femoral head (arrows) revealing medullary infarct (C). T2-weighted fat suppressed images yield geographic appearance compatible with avascular necrosis right proximal tibia and distal femur on sagittal (D) and coronal view (E), left proximal tibia and distal femur on sagittal (F) and coronal view (G) respectively.](RU-57-86431-g001){#f0001}

Further laboratory investigations were all normal except for the presence of thalassemia trait. Bone densitometry revealed a total vertebral Z score of --2.9. One month later, the patient clinically improved with ibuprofen and physical exercise in addition to dietary vitamin D and calcium supplementation. Laboratory results are summarized in [Table I](#t0001){ref-type="table"}. The consent for the presentation of this case was obtained from both parents and the patient.

###### 

Laboratory parameters of the patient with juvenile systemic lupus erythematosus at diagnosis and occurrence of multifocal avascular necrosis

  Parameters                          First administration   At AVN diagnosis   Normal values
  ----------------------------------- ---------------------- ------------------ ------------------
  Hemoglobin (g/dl)                   11.5                   11.3               12--15.5
  Leukocytes(/mm^3^)                  3,120                  6,100              4,000--11,500
  Thrombocytes(/mm^3^)                143,000                240,000            150,000--450,000
  ESR (mm/h)                          30                     21                 0--15
  CRP (mg/dl)                         0.4                    0.71               0--0.5
  SGOT (U/ml)                         197                    15                 5--40
  SGPT (U/ml)                         111                    11                 5--40
  C3 (mg/dl)                          17.4                   113                88--201
  C4 (mg/dl)                          4.3                    16.3               14.9--22.1
  ANA (IFA)                           pos                    neg                \< 1/100 titer
  Anti-dsDNA (IU/ml)                  193                    20.4               0--15
  Anti-Sm (U/ml)                      4.9                    0.34               0--15
  Anti-RNP                            5.7                    0.35               0--15
  Anti-SSA                            33                     1.38               0--15
  Anti-SSB                            10                     1.74               0--15
  AMA (U/ml)                          4.8                    ND                 0--5
  Anti-LKM1 (IFA)                     neg                    ND                 \< 1/10 titer
  SMA (IFA)                           pos                    ND                 \< 1/40 titer
  Anticardiolipin IgG (U/ml)          8.9                    2                  0--10
  Anticardiolipin IgM (U/ml)          5.3                    1.8                0--7
  Anti-β2 glycoprotein 1 (U/ml)       0.2                    neg                0--5
  Lupus anticoagulant                 ND                     neg                ND
  Total triglyceride (mg/dl)          ND                     90.8               50--150
  LDL (mg/dl)                         ND                     102                80--150
  HDL (mg/dl)                         ND                     55                 35--60
  Total cholesterol (mg/dl)           ND                     175                150--200
  Hb electrophoresis (%) (HbA/HbA2)   ND                     96.1/3.9           95--98/1.5--3.5
  Serum calcium (mg/dl)               12                     8.9                8.8--10.3
  Serum phosphorus (mg/dl)            3.4                    3.7                2.4--4.7
  Alkaline phosphatase (IU/l)         126                    54                 67--372
  Serum vitamin D (ng/ml)             ND                     18.3               20--60

AVN -- avascular necrosis, ESR -- erythrocyte sedimentation rate, CRP -- C-reactive protein, SGOT -- serum glutamic oxaloacetic transaminase, SGPT -- serum glutamic pyruvic transaminase, C3 -- complement 3, C4 -- complement 4, ANA -- antinuclear antibody, anti-DNA -- anti-double stranded DNA antibody, anti-Sm -- anti-Smith, anti-RNP -- anti-ribonucleoprotein, anti-SSA -- anti-Sjögren's-syndrome-related antigen A, anti-SSB -- anti-Sjögren's-syndrome-related antigen B, AMA -- antimitochondrial antibody, anti-LKM1 -- anti-liver kidney muscle 1, SMA -- smooth muscle antibody, LDL -- low-density lipoprotein, HDL -- high-density lipoprotein, Hb -- hemoglobin, ND -- not determined.

Discussion {#sec3}
==========

The pathogenetic mechanisms of AVN are still not exactly understood, but vascular injury, hypercoagulability, fat embolism and inhibition of angiogenesis have been suggested \[[@cit0002]\]. Although corticosteroid treatment is thought to be the major independent risk factor in SLE patients, AVN has also been reported even in the absence of steroid use, as an early musculoskeletal manifestation in SLE \[[@cit0003]--[@cit0006]\].

Another prospective study showed that patients with antiphospholipid syndrome (APS) without previous steroid treatment were also predisposed to AVN. This situation raised the question whether APS is a major risk factor for AVN development \[[@cit0007]\].

Additionally, CNS involvement, nephritis, vitamin D deficiency, hypertriglyceridemia, hypertension, and immunosuppressive drugs have been suggested to influence AVN development in SLE \[[@cit0002], [@cit0004], [@cit0008]\]. Previously, antiphospholipid antibodies (APLs) were linked with AVN, but recent studies disproved that \[[@cit0002], [@cit0004]--[@cit0008]\]. Also, in a recent meta-analysis, arthritis, cushingoid appearance, gastrointestinal involvement, hypertension, oral ulcers, nephritis, vasculitis, cytotoxic drugs, and steroid treatment with both cumulative and daily dose were found to be related to AVN development. In contrast, APLs, CNS involvement and Raynaud's phenomenon are not associated with AVN \[[@cit0009]\].

Diagnosis of AVN is based on imaging. Plain radiographs may show late changes including mottling of the bone trabecular pattern, depression or fragmentation, joint space narrowing and irregular sclerosis. MRI is more sensitive in the early phase of AVN and the most demonstrative finding is geographic areas of low and high signal intensities, whereas bone marrow edema, subchondral collapse and effusion may also be seen \[[@cit0002], [@cit0004], [@cit0005]\]. Our patient had normal X-ray but typical MRI findings. Therefore we suggest that AVN should be considered in jSLE patient with arthralgia and normal X-ray and it is advisable to perform MR examination in such cases.

The frequency of AVN in SLE (6%) was encountered in only one multicenter adult study from our country \[[@cit0010]\]. We do not know the exact AVN rate in juvenile SLE patients; thus the possible risk factors were not examined in the pediatric population in our country.

To date, only 4 relevant studies have investigated AVN frequency and risk factors in solely juvenile SLE patients. In the preliminary study including 14 jSLE with AVN diagnosed with X-ray, cumulative steroid dose was linked with AVN, but duration of steroid and azathioprine therapy, disease severity, CNS involvement, Raynaud's phenomenon and vascular thromboses had no effect on AVN development \[[@cit0011]\].

Castro et al. \[[@cit0004]\] prospectively performed whole body MRI in 40 juvenile SLE patients and suggested that steroid treatment did not influence AVN in jSLE. The small sample size was the major limitation of this study. Two recent jSLE cohorts eliminated this limitation and showed AVN frequency of 6% and 8.5% in 617 and 201 patients respectively.

Yang et al. \[[@cit0003]\] reported a higher rate of CNS disease, nephritis, maximal daily prednisolone dose, high-dose *i.v.* methylprednisolone therapy frequency, high-dose (oral) corticosteroids and immunosuppressive drug administration in the AVN group than without. Disease activity, malar rash, arthritis, Raynaud phenomenon, ANA and anti-ENA positivity were similar between these groups \[[@cit0003]\]. Similarly, nephritis was linked to AVN in the other study. Besides hypertension, vitamin D deficiency and elevated serum triglycerides were higher in the AVN group. Interestingly, corticosteroid use was similar between patients with and without AVN \[[@cit0002]\]. Studies investigating possible risk factors for AVN in jSLE patients are summarized in [Table II](#t0002){ref-type="table"}.

###### 

Brief review of studies evaluating possible risk factors for avascular necrosis in juvenile systemic lupus erythematosus patients in the literature

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                      Patients with AVN/total number of patients   Diagnostic modality                                 Meanage at diagnosis of AVN   Meandisease duration to AVN   Multifocal AVN(\> 2 sites)   Most affected joints   Need for surgical intervention   Risk factors found statistically significant for AVN development   Parameters not linked with AVN
  --------------------------- -------------------------------------------- --------------------------------------------------- ----------------------------- ----------------------------- ---------------------------- ---------------------- -------------------------------- ------------------------------------------------------------------ -----------------------------------
  Bergstein \[[@cit0011]\]\   14/35 (40%)\                                 X-ray survey                                        ND                            6.4 years                     4/14 (28.6%)                 Hip (57.1%)            ND                               Cumulative dose of prednisone                                      Duration of prednisone therapy\
  1974                        (9 patients were symptomatic)                                                                                                                                                                                                                                                                                        Duration of azathioprine therapy\
                                                                                                                                                                                                                                                                                                                                                   Disease severity\
                                                                                                                                                                                                                                                                                                                                                   CNS involvement\
                                                                                                                                                                                                                                                                                                                                                   Reynaud's phenomenon\
                                                                                                                                                                                                                                                                                                                                                   Vascular thromboses

  Castro \[[@cit0004]\]\      7/40 (17.5%)\                                Whole-body MRI                                      15.3 years                    2.7 years                     4/7 (57.2%)                  Knee (85.7%)           1/7 (14.3%)                      ND                                                                 Hyperlipidemia\
  2011                        (only one patient symptomatic)                                                                                                                                                                                                                                                                                       aPL antibodies\
                                                                                                                                                                                                                                                                                                                                                   Raynaud phenomenon\
                                                                                                                                                                                                                                                                                                                                                   Disease activity and damage\
                                                                                                                                                                                                                                                                                                                                                   Body mass index\
                                                                                                                                                                                                                                                                                                                                                   Duration of steroid therapy\
                                                                                                                                                                                                                                                                                                                                                   Maximum daily steroid dose\
                                                                                                                                                                                                                                                                                                                                                   High-dose IV pulse steroids

  Yang \[[@cit0003]\]\        37/617 (6%)                                  X-ray/MRI/Bone scan/CT for only symptomatic joint   16.1 years                    2.3 years                     30/37 (81%)                  Hip (70%)              9/37 (24%)                       CNS disease\                                                       Disease activity\
  2015                                                                                                                                                                                                                                                                          Nephritis\                                                         Malar rash\
                                                                                                                                                                                                                                                                                Maximal daily steroid dose\                                        Arthritis\
                                                                                                                                                                                                                                                                                High-dose IV steroid therapy frequency\                            Raynaud phenomenon\
                                                                                                                                                                                                                                                                                High-dose oral steroids\                                           ANA and anti-ENA positivity
                                                                                                                                                                                                                                                                                Immunosuppressive treatment                                        

  Gurion \[[@cit0002]\]\      17/201 (8.5%)                                ND                                                  16.5 years                    2 years                       4/17 (23.5%)                 ND                     ND                               Hypertension\                                                      Disease activity\
  2015                                                                                                                                                                                                                                                                          Nephritis\                                                         Steroid use\
                                                                                                                                                                                                                                                                                Vitamin D deficiency\                                              Hyperhomocysteinemia\
                                                                                                                                                                                                                                                                                Elevated serum triglycerides                                       aPL antibodies
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AVN -- avascular necrosis, MRI -- magnetic resonance imaging, aPL -- antiphospholipid, CT -- computed tomography, CNS -- central nervous system involvement, ANA -- antinuclear antibody, ENA -- extractable nuclear antigens, ND -- not detected.

In regard to aforementioned conflicting results in the literature, further studies are needed to define the risk factors for AVN in jSLE, which may lead to clarifying the pathogenesis and preventing AVN in pediatric cases.

Our patient had several risk factors for AVN including oral ulcers, arthritis, steroid and cytotoxic treatment and CNS involvement. Since CNS involvement, requirement for cytotoxic treatment and higher cumulative steroid dose can be linked to a severe disease phenotype, higher inflammation may lead to AVN development.

By contrast, no associations were found between oral aphthous and AVN in SLE patients in a recent meta-analysis \[[@cit0012]\]. Similarly, a recent comprehensive study, including 1219 adults with SLE, also concluded that high-dose corticosteroid and immunosuppressant use are the principal risk factors for developing AVN \[[@cit0013]\].

Hemoglobin concentration and electrophoresis in our patient revealed β-thalassemia trait which was not previously linked to AVN. Nonetheless, we would expect that thalassemia trait may be protective against AVN due to mild anemia, contrary to our case. Further multicenter case-control studies are needed to confirm the influence of thalassemia trait on AVN development in jSLE patients from the Mediterranean region.

In view of the heterogeneity of the results of different studies and even the aforementioned meta-analysis, there is no consensus about the exact pathogenesis of AVN in SLE and even more so in the juvenile form of the disease.

Conclusions {#sec4}
===========

The described case of a young female patient with jSLE treated with steroids and cyclophosphamide points to frequent AVN risk factors, but may also be a contribution to a wider discussion of the risk of AVN in such patients. AVN should be considered in differential diagnosis of arthritis in patients with SLE and jSLE particularly in the case of prolonged use of steroids and cyclophosphamide administration.
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